Guo Song, Chen Qiuli, Zhang Jun, Wei Meihua, Zheng Rujiang, Wang Bing, Li Yanhong, Ma Huamei, Jiang Xiaoyun
Department of Pediatrics, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Department of Child Healthcare, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China.
Front Endocrinol (Lausanne). 2024 Nov 22;15:1442166. doi: 10.3389/fendo.2024.1442166. eCollection 2024.
Metabolic disorders are common in individuals with Turner syndrome (TS). Hyperuricemia is associated with metabolic syndrome. This study investigated the serum uric acid (SUA) profile in patients with TS.
A retrospective observational study was conducted with 145 patients with TS. A total of 72 normal girls were in the control group from 2015 to 2024: 86 TS patients were treated with growth hormone (GH), 80 with stanozolol, and 52 with estrogen.
Hyperuricemia was present in 33.1% (47/145) of patients with untreated TS and in 16.67% (12/72) of the controls ( < 0.001). Multivariable linear regression analysis showed that BMISDS, fasting serum glucose, and eGFR explained 34.4% (model = 0.344) of the total variation in SUA in the untreated TS group. SUA and SUASDS (SUA standard deviation score) levels generally showed a slow rising tendency with age. SUA increased significantly in the first year of stanozolol initiation ( = 0.032), while adding estrogen and stanozolol improved the lipid profile during the whole assessment period.
Girls with TS showed a slow rising tendency in SUA and SUASDS with age and had higher SUA and SUASDS levels and incidence of hyperuricemia compared to their healthy female peers. The independent risk factors for hyperuricemia in pediatric patients with TS were BMISDS, HOMA-IR, glucose, and eGFR. The incidence of hyperuricemia increased in the first year of stanozolol treatment.
代谢紊乱在特纳综合征（TS）患者中很常见。高尿酸血症与代谢综合征相关。本研究调查了TS患者的血清尿酸（SUA）情况。
对145例TS患者进行了一项回顾性观察研究。2015年至2024年共有72名正常女孩作为对照组：86例TS患者接受生长激素（GH）治疗，80例接受司坦唑醇治疗，52例接受雌激素治疗。
未经治疗的TS患者中33.1%（47/145）存在高尿酸血症，对照组中为16.67%（12/72）（<0.001）。多变量线性回归分析显示，在未经治疗的TS组中，体质指数标准差（BMISDS）、空腹血糖和估算肾小球滤过率（eGFR）解释了SUA总变异的34.4%（模型=0.344）。SUA和SUA标准差评分（SUASDS）水平通常随年龄呈缓慢上升趋势。开始使用司坦唑醇的第一年SUA显著升高（=0.032），而在整个评估期间，添加雌激素和司坦唑醇可改善血脂情况。
与健康女性同龄人相比，TS女孩的SUA和SUASDS随年龄呈缓慢上升趋势，且SUA和SUASDS水平更高，高尿酸血症发生率更高。小儿TS患者高尿酸血症的独立危险因素为BMISDS、胰岛素抵抗指数（HOMA-IR）、血糖和eGFR。司坦唑醇治疗的第一年高尿酸血症发生率增加。
